Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: An open-label comparison with inhaled salmeterol

Treatments in Respiratory Medicine

Volumn 4, Issue 6, 2005, Pages 447-455

  Fukuchi, Yoshinosuke ^a   Nagai, Atsushi ^b   Seyama, Kuniaki ^a   Nishimura, Masaharu ^c   Hirata, Kazuto ^d   Kubo, Keishi ^e   Ichinose, Masakazu ^f   Aizawa, Hisamichi ^g  

^a JUNTENDO UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Osaka Prefecture University   (Japan)

^e SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CREATININE; HOKUNALIN; SALMETEROL; SALMETEROL XINAFOATE; TULOBUTEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FEMALE; FORCED EXPIRATORY VOLUME; GROUPS BY AGE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PATIENT COMPLIANCE; PHARYNX DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TRANSDERMAL PATCH; TREMOR; UPPER LIP;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; ADULT; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; TERBUTALINE; TIME FACTORS;

EID: 29144504032     PISSN: 11763450     EISSN: 11763450     Source Type: Journal    
DOI: 10.2165/00151829-200504060-00008     Document Type: Article

References (28)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD [online]. National Heart Lung and Blood Institute/World Health Organization; 2003. Available from URL: http://www.goldcopd.com [Accessed 2005 Jun 6]
2. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-46
3. The Japan Respiratory Society COPD Guideline Development Committee. The guidelines for diagnosis and treatment of chronic obstructive pulmonary disease (COPD) [in Japanese]. 2nd ed. Osaka: Medical Review Sha, 2004: 69-70
4. 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur J Clin Pharmacol 1993; 44: 361-4
5. Iikura Y, Ebisawa M, Saito H. Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. Ann Allerg Asthma Immunol 1995; 74: 147-51
6. Miyamoto T, Takishima T, Makino S, et al. Clinical study of salmeterol xinafoate (SN408) aerosol: double blind parallel study between procaterol tablet in patients with bronchial asthma [in Japanese]. J Clin Ther Med 2002; 18: 411-36
7. Urik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomized, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750-4
8. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-21
9. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-62
10. Miyamoto T, Takishima T, Takahashi T, et al. Clinical evaluation of HN-078, a patch formulation of tulobuterol, in patients with bronchial asthma in a phase III study: a multicenter double-blind parallel study between procaterol hydrochloride tablet [in Japanese]. J Clin Ther Med 1995; 11: 783-807
11. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55
12. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-65
13. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-92
14. Patakas D, Andreadis D, Mavrofridis E, et al. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir Med 1998; 92: 1116-21
15. Ayers ML, Mejia R, Ward J, et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001; 17: 1132-7
16. Di Lorenzo G, Morici G, Drago A, et al. Efficacy, tolerability and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther 1998; 20: 1130-48
17. van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-85
18. Matera MG, Caputi M, Cazzola M. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease. Respir Med 1996; 90: 497-9
19. Sasaki H, Nakamura M, Kida K, et al. Standard values of spirogram and arterial blood gas analysis in Japanese population [in Japanese]. Nihon Kokyuki Gakkai Zasshi 2001; 39: 1-17
20. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-9
21. Laube BL, Swift DL, Wagner Jr HN, et al. The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma. Am Rev Respir Dis 1986; 133: 740-3
22. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-11
23. Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis 1990; 142: 571-5
24. Kume H, Kondo M, Ito Y, et al. Effects of sustained-release tulobuterol on asthma control and β-adrenoceptor function. Clin Exp Pharmacol Physiol 2002; 29: 1076-83
25. Kume H. Clinical use of beta2-adrenergic receptor agonists based on their intrinsic efficacy. Allergology Int 2005; 54: 89-97
26. Tamura G, Yamauchi K, Honma M, et al. Long-term study of NH-078, a patch formulation of tulobuterol, in adult bronchial asthma [in Japanese]. J Clin Ther Med 1995; 11: 1067-80
27. 2-agonist tulobuterol in patients with mild or moderate persistent bronchial asthma. Arzneimittel Forschung 2004; 54: 280-5
28. 2-agonist) in patients with chronic obstructive pulmonary disease [abstract]. Proc Am Thorac Soc 2005; 2: A543